ArticleJapanese journal of radiology2013
Intrahepatic periportal high intensity on hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI: imaging findings and prevalence in various hepatobiliary diseases.
Article in Japanese journal of radiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 17 citations in OpenAlex.
- Intrahepatic diffuse periportal hyperintensity patterns on hepatobiliary phase of gadoxetate-enhanced MRI: a non-invasive imaging biomarker for clinical stratification of liver injury.Abdominal radiology (New York) · 2025Article
- The value of periportal hyperintensity sign from gadobenate dimeglumine-enhanced hepatobiliary phase MRI for predicting clinical outcomes in patients with decompensated cirrhosis.Insights into imaging · 2024Article
- Spectrum of liver lesions hyperintense on hepatobiliary phase: an approach by clinical setting.Insights into imaging · 2021Review
- Morphometric changes and imaging findings of diffuse liver disease in relation to intrahepatic hemodynamics.Japanese journal of radiology · 2020Review
- Patterns of enhancement in the hepatobiliary phase of gadoxetic acid-enhanced MRI.The British journal of radiology · 2020Review
- Liver assessment using Gd-EOB-DTPA-enhanced magnetic resonance imaging in primary biliary cholangitis patients.Japanese journal of radiology · 2019Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo reveal the incidence and degree of intrahepatic periportal high intensity (PHI) on hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI (EOB-MRI) in patients with or without various hepatobiliary diseases. MATERIALS AND
methodsPatients with normal liver (N = 256) and those with hepatic disorder (N = 857) who underwent EOB-MRI were the subjects in this study. Incidence of PHI was evaluated among the patients with normal liver and those with hepatic disorder. Degree of PHI was categorized into four grades and compared among the various hepatic diseases. Enhancement ratios (ER) of the PHI area, background liver with PHI, and background liver in control cases without PHI were evaluated.
resultsPHI was observed in 2.7 % of the patients with hepatic disorder. No PHI was observed in the patients with normal liver. The incidence rates of PHI among various hepatobiliary diseases were as follows; liver cirrhosis 3.1 %, chronic hepatitis 1.0 %, primary biliary cirrhosis 12.5 %, idiopathic portal hypertension 33.3 %. The ER of the PHI area and background liver were 3.92 and 2.48 (p = 0.0002). There were no significant differences between the ER of the PHI area and the ER of background liver in the noncirrhotic control without PHI.
conclusionIn 2.7 % of the patients with a hepatic disorder, the periportal area was saved from decrease of EOB uptake and it showed PHI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.